{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:26:14Z","timestamp":1787390774071,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clon.2026.104280","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:13:40Z","timestamp":1782573220000},"page":"104280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Controlled Trial"],"prefix":"10.1016","volume":"57","author":[{"given":"V.","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-7914","authenticated-orcid":false,"given":"P.","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-0911","authenticated-orcid":false,"given":"S.","family":"Priya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9381-3678","authenticated-orcid":false,"given":"S.","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dhanawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Adepu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Phurailatpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0191-2744","authenticated-orcid":false,"given":"V.","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104280_bib1","article-title":"The contemporary management of prostate cancer","author":"Chakrabarti","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"10.1016\/j.clon.2026.104280_bib2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2008.17.4052","article-title":"Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31","volume":"27","author":"Souhami","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clon.2026.104280_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of Androgen Suppression in the Treatment of Prostate Cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clon.2026.104280_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104280_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","article-title":"High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial","volume":"23","author":"Zapatero","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104280_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104280_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clon.2026.104280_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104280_bib9","article-title":"Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis","author":"Zaorsky","year":"2025","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104280_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","article-title":"Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium","volume":"87","author":"Ong","year":"2025","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clon.2026.104280_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"issue":"10323","key":"10.1016\/j.clon.2026.104280_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.clon.2026.104280_bib13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2026.104280_bib14","article-title":"Cost-utility analysis of adding abiraterone acetate plus prednisone\/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data","volume":"17","author":"Clarke","year":"2022"},{"key":"10.1016\/j.clon.2026.104280_bib15","doi-asserted-by":"crossref","first-page":"S1743","DOI":"10.1016\/j.annonc.2025.09.102","article-title":"LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)","volume":"36","author":"Nguyen","year":"2025","journal-title":"Ann Oncol"},{"issue":"10231","key":"10.1016\/j.clon.2026.104280_bib16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"The Lancet"},{"issue":"28","key":"10.1016\/j.clon.2026.104280_bib17","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO-25-00274","article-title":"Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial","volume":"43","author":"Menne Guricov\u00e1","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clon.2026.104280_bib18","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104280_bib19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2023.08.046","article-title":"Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP\/TRIGU0907)","volume":"118","author":"Yorozu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clon.2026.104280_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104280_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104280_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of 68 Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.clon.2026.104280_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"15","key":"10.1016\/j.clon.2026.104280_bib24","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2026.104280_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104623","article-title":"Augmented radiotherapy \u00bb in the management of high-risk prostate cancer (PCa): A systematic review","volume":"207","author":"Le Gu\u00e9velou","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.clon.2026.104280_bib26","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2020.11.059","article-title":"Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer","volume":"109","author":"Koontz","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104280_bib27","series-title":"Parallel phase III randomized trials of genomic-risk stratified unfavorable intermediate risk prostate cancer: de-intensification and intensification clinical trial evaluation (GUIDANCE) [clinical trial registration]","year":"2025"},{"issue":"3","key":"10.1016\/j.clon.2026.104280_bib28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:55:45Z","timestamp":1787388945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526002517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S0936655526002517"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104280","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104280"}}